Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) just unveiled an announcement.
Zhaoke Ophthalmology has expanded its commercialization strategy for its core presbyopia candidate BRIMOCHOL™ PF by granting exclusive distribution rights to AFT Pharmaceuticals in Singapore and Senju Pharmaceutical in Vietnam, covering registration, import, promotion, marketing and sales. The deals make AFT and Senju the seventh and eighth commercialization partners for the product, reinforcing Zhaoke’s global expansion drive at a time when presbyopia affects hundreds of millions of adults in Asia-Pacific and there are no approved pharmacological treatments in many markets, positioning the company to benefit from significant unmet demand if the drug secures regulatory approvals in key territories.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a specialist ophthalmic pharmaceutical company focused on treatments for eye diseases, with a core asset in BRIMOCHOL™ PF, an investigational preservative-free eyedrop aimed at correcting presbyopia-related near-vision loss. The company is pursuing a global commercialization strategy for BRIMOCHOL™ PF through multiple regional partners, targeting significant unmet demand for presbyopia therapeutics across Asia-Pacific and other key markets.
Average Trading Volume: 910,662
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.92B
See more insights into 6622 stock on TipRanks’ Stock Analysis page.